Thymolipoma and its Association with Myasthenia Gravis: a Multi-center Experience

Shadi Hamouri¹, Sebawe Syaj¹, Leen Al-Kraimeen², Moaath Al-Smady³, Hani Alhadidi⁴, Farid Barakat⁵

ABSTRACT

Background: Thymolipoma is a rare benign thymic tumor that arises in the anterior mediastinum. It presents with non-specific symptoms such as chest pain and dyspnea due to compression of the tumor on surrounding structures. In addition, this tumor is associated with paraneoplastic syndromes, including myasthenia gravis. Such a relationship is still not understood and requires investigation. Objective: Investigate the significance of myasthenia gravis in thymolipoma patients. Methods: We present a series of 16 thymolipoma cases from multiple medical centers. Data extraction included demographic, diagnostic, radiological and laboratory, and clinical outcome variables. We also used the modified Osserman score to assess the severity of myasthenia gravis. Results: Ten patients were males, and six were females; the sample mean age was 39.9 years (SD = 16.7). Upon presentation, 7/16 patients were asymptomatic, 4/16 patients had chest pain, and 2/16 had dyspnea. Seven patients were having myasthenia gravis; they experience generalized weakness (3/7), diplopia (2/7), ptosis (1/7), and bulbar weakness (1/7). Serum acetylcholine receptor antibody (AChRAb) was positive in 4 patients. All patients underwent thymectomy either via sternotomy or thoracotomy. After proper follow-up, only 2/7 of myasthenic patients had a complete remission of symptoms, no tumor recurrence was observed.

Conclusion: Although the effect of using steroids in myasthenic patients on thymolipomotic transformation still needs confirmation, diagnosis of thymolipoma should be kept in mind in myasthenic patients presenting with relevant symptoms and taking steroids. Furthermore, complete remission of myasthenic symptoms after removal of thymolipoma needs further investigation.

Keywords: Thymolipoma, Myasthenia gravis, Thymus Neoplasms, Steroids, Surgical resection.

1. BACKGROUND

Thymolipoma is a rare mediastinal mass that constitutes less than 10% of thymic tumors. This encapsulated tumor is benign, slow-growing, and does not recur after complete surgical resection. It has an incidence of approximately 0.12 per 100,000 persons each year (1, 2). It was first described as a simple thymic lipoma in 1916 (3), but then it was distinguished as “thymolipoma” by Hall in 1948 (4). This tumor presents in the anterior mediastinum, with vague symptoms like dyspnea, chest pain, and fatigue; it also presents with paraneoplastic syndromes such as Graves’ disease, pure red blood cell aplasia, aplastic anemia, hypogammaglobulinemia, Hodgkin’s disease, and myasthenia gravis (5). These syndromes make thymolipoma of clinical importance, especially with the lack of studies on this rare tumor. Furthermore, symptoms of myasthenia gravis were relieved after surgical resection of thymolipoma, which puts this association under the spotlight and makes it in need of explanation (1). In this descriptive retrospective study, we collected clinical data from multiple centers in Jordan. These data include laboratory results, clinical manifestations, and radiological findings.

2. OBJECTIVE

The aim of the study was to investigate the significance of myasthenia gravis in thymolipoma patients.

3. MATERIAL AND METHODS

Patients and Study design

This study addresses 16 patients from tertiary medical centers in Jordan. Centers including King Abdullah University Hospital (KAUH), King Hussein...
Cancer Center (KHCC), Jordan University Hospital, and the Royal Medical Services (RMS).

Data from medical records were extracted retrospectively from June 2002 to June 2021. A standardized Excel sheet was used for data collection. Variables included demographics like age, sex, and institution, presenting symptoms, comorbidities, patient diagnostics including computer tomography (CT) notes and serum acetylcholine receptor antibody (AChRAb) levels, type of myasthenia gravis and its severity, administered drugs, surgical approach, remission status of myasthenia, and follow-up period. An ethical approval was granted from the institutional review board (IRB) affiliated to our institute (IRB no. 2021/179).

Screening and Management
The diagnosis of thymolipoma was based on the CT of the chest. All patients were screened for AChRAb.

A modified Osserman classification score was used to assess the severity of myasthenia gravis (6). Our patients were treated surgically using one of the following procedures: (1) Full median sternotomy with extended thymectomy. It includes resection of the thymus and the thymolipoma with the anterior mediastinal fat between phrenic nerves and pleurae, the pericardium, and the diaphragm. In patients with myasthenia gravis, more extensive surgery has been performed, including the right and left pericardiophrenic angles, the aortopulmonary window, the aortocaval groove, and retroinnominate space, and the perithyroid area (2). Anterolateral thoracotomy with standard thymectomy, including the thymolipoma. The chest cavity is accessed through the 5th intercostal space (3). Right-sided video-assisted thoracoscopic extended thymectomy using three ports (2 in the 5th intercostal space in the mid-and anterior axillary

| ID | Age (y) | Sex | Presenting symptoms | Comorbidities | Type of MG | MG Severity |
|----|---------|-----|---------------------|---------------|------------|-------------|
| Case #1 | 27 | M | Asymptomatic | - | - | - |
| Case #2 | 29 | M | Ptosis, diplopia, headache | MG | Ocular | Class I |
| Case #3 | 6 | F | Asymptomatic | Asthma | - | - |
| Case #4 | 56 | F | Generalized weakness, diplopia | MG, HTN | Ocular | Class I |
| Case #5 | 48 | M | Generalized weakness, bulbar | MG | Bulbar | Class III |
| Case #6 | 26 | M | Asymptomatic | - | - | - |
| Case #7 | 32 | M | Asymptomatic | - | - | - |
| Case #8 | 47 | M | Progressive generalized weakness | MG, Hyperparathyroidism | Generalized | Class II |
| Case #9 | 51 | M | Asymptomatic | MG, Lung Fibrosis, ß-thalassemia | Generalized | Class IIIa |
| Case #10 | 31 | M | Asymptomatic | MG | Generalized | Class I |
| Case #11 | 17 | F | Asymptomatic | MG | Generalized | Class III |
| Case #12 | 47 | F | Chest pain | HTN, DM, IHD | - | - |
| Case #13 | 72 | F | Chest pain, dyspnea | DM, HTN, IHD, interstitial pulmonary disease, pulmonary HTN | - | - |
| Case #14 | 61 | M | Chest pain | HTN, IHD, Crohn’s Disease | - | - |
| Case #15 | 52 | M | Chest pain, dyspnea | HTN, IHD | - | - |
| Case #16 | 36 | F | Chest infection, high fever | - | - | - |

Table 1. Patients’ characteristics

MG: Myasthenia Gravis, HTN: Hypertension, DM: Diabetes mellitus, IHD: Ischemic heart disease.
Thymolipoma and its Association with Myasthenia Gravis: a Multi-center Experience

Resection of the entire anterior mediastinal content between the sternum, pericardium, diaphragm, pleurae, and phrenic nerves, including thymus and thymolipoma. Most of the dissection was performed using an energy device.

Lines and 1 in the 3rd intercostal space, mid axillary line. Resection of the entire anterior mediastinal content between the sternum, pericardium, diaphragm, pleurae, and phrenic nerves, including thymus and thymolipoma. Most of the dissection was performed using an energy device.

Data analysis

Tables were employed to summarize individual patient data. Summar statistics were used, such as medians for continuous variables and frequencies or percentages for categorical data. A scatter plot was generated using the “ggplot2” package in R software (version 4.0.5) (7, 8).

### Table 2. Diagnostic procedures and tumor characteristics. AChRAb: Acetylcholine receptor antibody.

| ID  | Age  | Sex | CT Notes                                                                 | Tumor weight (g) | Dimensions (cm) | Serum AChRAb | Lymphocytes | WBCs  |
|-----|------|-----|--------------------------------------------------------------------------|------------------|-----------------|--------------|-------------|-------|
| Case #1 | 27  | M   | 1.5 cm soft tissue lesion in the anterior mediastinum                    | 2700             | 34 × 23 × 9     | -            | 0.118       | 11.3  |
| Case #2 | 29  | M   | Large soft lesion with mixed soft tissue and fat component occupying most of the right hemithorax | 150               | 18 × 5 × 1.5    | +            | 0.112       | 20    |
| Case #3 | 6   | F   | 8 × 7 cm Mediastinal mass                                               | 1100             | 28 × 12 × 6     | -            | 0.663       | 17.1  |
| Case #4 | 56  | F   | 20 × 215 cm Huge Mediastinal Mass                                         | 120              | 7 × 5 × 1       | +            | 0.38        | 13.2  |
| Case #5 | 48  | M   | Aortopulmonary mass                                                     | 400              | 17 × 19 × 1     | +            | 0.22        | 11.4  |
| Case #6 | 26  | M   | 5 × 3 cm Mediastinal Mass                                                | 100              | 7 × 4 × 1       | -            | 0.29        | 7.8   |
| Case #7 | 32  | M   | 10 × 20 cm Mediastinal Mass                                              | 350              | 20 × 13 × 1     | -            | 0.34        | 10.1  |
| Case #8 | 47  | M   | Aortopulmonary mass                                                     | 62               | 9 × 7.5 × 2     | +            | 0.21        | 9.7   |
| Case #9 | 51  | M   | 2 × 4 well defined lesion in the anterior mediastinum                   | 156              | 2 × 4           | +            | 0.31        | Leukocytosis 16.5 |
| Case #10 | 31 | M   | No evidence of mediastinal mass lesion                                  | 58.5             | 10.5 × 6.5 × 2  | +            | 0.21        | 10.1  |
| Case #11 | 17 | F   | No evidence of mediastinal mass lesion                                  | 11               | 8 × 7 × 1       | +            | 0.35        | 13.4  |
| Case #12 | 47 | F   | None                                                                     | 8.5              | 5 × 3 × 0.5     | -            | 0.19        | 10.0  |
| Case #13 | 72 | F   | None                                                                     | 45               | 4 × 2 × 1       | -            | 0.24        | 11.8  |
| Case #14 | 61 | M   | None                                                                     | 38.5             | 12 × 3 × 1      | -            | 0.20        | 7.5   |
| Case #15 | 52 | M   | None                                                                     | 2.2              | 4 × 2 × 0.5     | -            | 0.33        | 6.5   |
| Case #16 | 36 | F   | A large left-sided thoracic mass, which was displacing the mediastinum towards the right side | 2900             | 32 × 23 × 8     | -            | 0.12        | 16.9  |

AChRAb: Acetylcholine receptor antibody.
Thymolipoma and its Association with Myasthenia Gravis: a Multi-center Experience

4. RESULTS

We reviewed 16 cases diagnosed with thymolipoma. The mean age was 39.9 years (SD = 16.7), and patients’ ages ranged from 6 to 72 years. Ten patients were males, and six patients were females. When presented, 7/16 patients were asymptomatic. Four patients suffered from compression symptoms such as chest pain (4/16) and dyspnea (2/16). Moreover, other four patients experienced myasthenic symptoms, including generalized weakness (3/16), diplopia (2/16), ptosis (1/16), and bulbar weakness (1/16). Case #2 had a headache in addition to his ptosis and diplopia. Furthermore, case #16 had a chest infection with a high fever. Comorbidities were hypertension in 5 patients, ischemic heart disease in 4 patients. Case #13 had both in addition to diabetes mellitus. Case #3 had asthma, and Case #8 had hyperparathyroidism. Case #9 had lung fibrosis in addition to ß-thalassemia. Case #14 had Crohn’s disease. Patients’ characteristics are summarized in Table 1.

Seven patients out of 16 had myasthenia gravis; 3 of them were asymptomatic upon presentation. Type of myasthenia gravis was generalized in 4 patients, ocular in 2 patients, and bulbar in one patient. As for severity, Osserman classification score revealed that patients with generalized myasthenia gravis were classified as I and II, one patient in each class, and two patients were classified as III and IIIa, respectively. Patients with an ocular type were in class I. Furthermore, one patient with a bulbar type had a class III disease.

For most patients, mediastinal masses of variable sizes were found in CT images (Figure 1 a, b) or were sometimes reported as “soft lesions”; case #8 was reported to show an aortopulmonary mass. For detection of myasthenia gravis, serum AChRAb was positive in all seven myasthenic patients. Two patients were investigated by

| ID   | Age | Sex | NMBs | Steroid Drugs | Steroid Treatment Period | Surgical Approach | Remission | Follow-Up Period |
|------|-----|-----|------|---------------|-------------------------|-------------------|-----------|-----------------|
| Case #1 | 27  | M   | None | None          | None                    | Sternotomy        | No        | 96 Months       |
| Case #2 | 29  | M   | Pyridostigmine | Prednisolone | 24 Months                | Sternotomy        | Yes       | 192 Months      |
| Case #3 | 6   | F   | None | None          | None                    | Sternotomy        | No        | 36 Months       |
| Case #4 | 56  | F   | None | Prednisolone  | 16 Months                | Sternotomy        | No        | 9 Months        |
| Case #5 | 48  | M   | None | Prednisolone  | 24 Months                | Right Thoracotomy | No        | 6 Months        |
| Case #6 | 26  | M   | None | None          | None                    | Right VAT         | No        | 16 Months       |
| Case #7 | 32  | M   | None | None          | None                    | Left Thoracotomy  | No        | 20 Months       |
| Case #8 | 47  | M   | Pyridostigmine | Prednisolone | 18 months                | Sternotomy        | No        | Till Now        |
| Case #9 | 51  | M   | Pyridostigmine | Prednisolone | NA                      | Sternotomy        | No        | Till Now        |
| Case #10 | 31  | M  | Pyridostigmine | Azathioprine  | Prednisolone            | NA                | Sternotomy | Yes 48 Months |
| Case #11 | 17  | F   | Pyridostigmine | Prednisolone | 24 months                | Sternotomy        | No        | Till Now        |
| Case #12 | 47  | F   | None | None          | None                    | Sternotomy        | No        | Till Now        |
| Case #13 | 72  | F   | None | None          | None                    | Sternotomy        | No        | 84 Months       |
| Case #14 | 61  | M   | None | None          | None                    | Sternotomy        | No        | Till Now        |
| Case #15 | 52  | M   | None | None          | None                    | Sternotomy        | No        | Till Now        |
| Case #16 | 36  | F   | None | None          | None                    | Sternotomy        | No        | Till Now        |

Table 3. Patient management and follow-up. NMBs: Neuromuscular blockers, VAT: Video-assisted Thoracotomy.
electromyography nerve stimulation (Table 2). Among seven patients with myasthenia gravis, 3/7 patients were on a neuromuscular blocker (pyridostigmine), and all of them were treated with corticosteroids to relieve myasthenic symptoms (Table 3). As for the primary treatment, all patients underwent thymectomy either through sternotomy, thoracotomy, or video-assisted thoracoscopic surgery. No postoperative complications were observed, except for case #2, who experienced chylothorax. After excision, tumor weights ranged from 220 to 2900 gm, with most tumors weighing less than 500 gm. Lesions were weighing above 1000 gm in 3 non-myasthenic patients (Figure 2 a, b). None of the patients experienced recurrence. Although only 2/7 patients had a complete remission of myasthenia gravis, they were followed up for 192 and 48 months, respectively. Images of some resected tumors are shown in Figure 3.

5. DISCUSSION
Thymolipoma is also known as lipoma of the thymus, benign thymoma, thymolipomatous hamartoma, lipothyrmoma, and mediastinal lipoma (9, 10). Moran et al. conducted a clinicopathological review that contained 33 cases and studied the radiological and histopathological aspects of thymolipoma in their sample (11). In another report of 9 patients, some patients had myasthenia gravis, and their symptoms were relieved after resection of the mass, which emphasizes this association. Furthermore, none of their patients experienced tumor recurrence (12). In 2014, Huang et al. made a vital comparison between thymomatous and non-thymomatous myasthenia gravis and their outcomes after surgical treatment, 12 of these patients had thymolipoma, and their mean duration of myasthenic symptoms was the greatest before the surgery among other groups of the study (p < 0.001) (13).

The pathogenesis of thymolipoma is still unclear, but it has been thought to follow one of two theories, the hyperplasia theory, which suggests defining the tumor as a lipoma of thymic fat and the mixed tumor theory that defines thymolipoma as a mixture of mesenchymal and endodermal neoplasm (14, 15). A cytogenetic analysis allowed a more accurate characterization of these lesions that carry varying amounts of mature thymic...
Thymolipoma and its Association with Myasthenia Gravis: a Multi-center Experience

Thymolipoma and its Association with Myasthenia Gravis: a Multi-center Experience

and adipose tissue. Also, it can demonstrate individual cases’ pathogenesis (16, 17). The first cytogenetic study of a thymolipoma was reported by Hull et al. in 1995, describing it as a proliferating thymolipoma due to the presence of adipose and abnormal thymic tissue (16). Another study done in 2009 used cytogenetic analysis to figure out the exact pathogenesis of their case, which was a neoplasm of thymic fat (17).

It is challenging to diagnose thymolipoma according to clinical symptoms or signs, and biopsy is the definitive diagnostic tool (18). However, up to 50% of thymolipoma patients remain asymptomatic, with the tumor getting bigger without invading surrounding structures until it is incidentally discovered in radiographic images (19). The other half of patients mainly present with cough, dyspnea, chest pain, hoarseness, and upper respiratory tract infection (20). These findings are consistent with ours, as almost half of our patients (7/16) were asymptomatic at presentation. Damadoglu et al. reported their experience of 10 cases and found fatigue to be the most prominent symptom among their cohort (1). Generally, when thymolipoma is symptomatic, respiratory symptoms predominate.

A plethora of studies have suggested a relationship between myasthenia gravis and thymolipoma (1, 21-23). As an autoimmune disease, myasthenia gravis is associated with antibodies directed against the acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and therefore characterized by muscle weakness and fatigue (24). The exact pathogenesis of this association is unclear, but some genetic findings revealed the presence of myoid cells, which might play a role as a stimulus to the autoimmune response in myasthenia gravis patients (1). In addition, therapies include steroids, which might hasten the effect of fatty degeneration in thymomas and enhance their shift into thymolipomas (13). Seven of our patients had myasthenia gravis; four of them were on steroids. The prevalence of myasthenia gravis associated with thymolipoma in our cohort was (43.8%) which supports the results reported by Damadoglu et al. and Rieker et al. (1, 12).

It was reported that thymolipoma occurs most frequently in patients aged 2 to 67 years, without sex predilection. A retrospective study of 27 patients found that the mean age of presentation is 26.7 years, with most patients presenting in the first four decades of life (10). Another case series found that ages range between 16 and 67 years with a mean age of 34.1 years (1). As to myasthenia gravis patients, Pan et al. found thymolipoma to appear in older age groups and have a lower mean weight of the tumor compared to non-myasthenic patients (3). Since myasthenic patients get diagnosed earlier, as soon as their symptoms manifest, the same phenomenon was observed in our cohort of patients as described in Figure 1. In the present report, the mean age was 39.9 years, higher than the previously published studies. The mean weight of thymic tissue removed was 136.8 g in myasthenic patients and 614.2 g in non-myasthenic patients.

About 85% of generalized myasthenia gravis patients have autoantibodies against post-synaptic acetylcholine receptors (AChRab) (25), the other 15% are described as having seronegative myasthenia gravis (SNMG), and about 45% of them have anti-MuSK-Abs (26). Neurological failure, diffuse limb weakness, bulbar weakness, and intermittent ptosis suggest the diagnosis of myasthenia gravis associated with elevated serum AChRab. Three out of seven of our myasthenic patients presented with generalized weakness, and their serology results showed an elevation in AChRab titers. Although the use of preoperative AChRab titers to predict the prognosis and severity of symptoms has not been well-documented, it is still a promising predictor that might be useful to discriminate between ocular and generalized types of myasthenia gravis (27).

The optimal treatment for thymolipoma is thymectomy using open surgical techniques like sternotomy or thoracotomy and minimally invasive techniques using video-assisted thoracoscopic surgery or robotic surgery. After complete resection, thymolipoma has a good prognosis with no malignant transformation or recurrence (20). Regarding the surgical outcomes in myasthenic patients, total resection might aid in improving their symptoms (28), as two out of seven among our MG cases exhibited remission. Case #2 had ocular myasthenia gravis, an extremely rare association, and his surgical outcomes are supported by a case report published by Mardi et al. of a patient with ocular myasthenia gravis associated with thymolipoma and their symptoms improved after the operation (28). Huang et al. looked at post-operative results of thymectomy in thymolipomatous, thymomatous, and non-thymomatous myasthenic patients and found the rate of stable remission to be significantly higher in the thymolipomatous group than thymomatous group (41.7% vs. 28.8%, p = 0.029). However, no reliable conclusion can be achieved yet. As for long-term effects, total resection potentially compromises future immunological competence. Thus, the immunological milieu should be monitored, especially in young patients (29, 30).

CONCLUSION

Our study reports a 19-year multicenter experience. To our knowledge, it is one of the largest cohorts of thymolipoma associated with myasthenia gravis. Although it bears some limitations, including the retrospective nature of data collection, especially data collected a long time ago, the small sample size raises some difficulties in the statistical analysis. In addition, a lack of symptoms of thymolipoma results in difficulty in diagnosing the pathology, which leads to underreporting. Therefore, we recommend conducting more research to understand the etiology of thymolipoma and the effect of surgical resection of thymolipoma on myasthenic symptoms to determine the subcategory of patients who can benefit from this modality.
• Declaration of patient consent: A waiver of patients’ consents was approved from the IRB due to the retrospective nature of data collection.

• Author’s Contribution: SH: Conceptualization, Project Administration, Data Collection, Data Analysis, Draft Writing, and Critical Revision. SS and LMK: Data Collection, Data Analysis, Draft Writing, and Critical Revision. MS, HH, FB: Conceptualization, Data Collection, Draft Writing, and Critical Revision.

• Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

• Financial support and sponsorship: This research project has received no funding.

REFERENCES

1. Damadoglu E, Salturk C, Tasik HB, Ertugrul M, Yilmaz A, Atasalih A, et al. Mediastinal thymolipoma: An analysis of 10 cases. Respir Med. 2007 Nov; 12(6): 924-927.

2. Miranda A, Marques J, Ferreira J, Cunha F, Ribeiro M, Ruivo R. Persistent radiologic thoracic hypotransparency: A case report and review of the literature. Arch Pediatr. 2018 Nov 1; 25(8): 489-492.

3. Pan CH, Chiang CY, Chen SS. Thymolipoma in patients with myasthenia gravis: report of two cases and review. Acta Neurol Scand. 1988; 78(1): 16-21.

4. Hall GFM. A case of thymolipoma. With observations on a possible relationship to intrathoracic lipoma. Br J Surg [Internet]. 1949 Jan 1 [cited 2021 Jun 25]; 36(143): 321-324. Available from: https://bsjs-journals.onlinelibrary.wiley.com/doi/full/10.1002/bjs.18003614318

5. McManus KG, Allen MS, Trastek VF, Deschamps C, Crotty TB, Pairolero PC. Lipohymothoma with red cell aplasia, hypogammaglobulinemia, and lichen planus. Ann Thorac Surg. 1994 Nov 1; 58(5): 1534-1536.

6. Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn JS, et al. Myasthenia gravis: Recommendations for clinical research standards [Internet]. Vol. 55. Neurology. Lippincott Williams and Wilkins; 2000 [cited 2021 Jun 26]. p. 16-23. Available from: https://jn.neurology.org/content/55/1/16

7. Wickham H. ggplot2. 2016 [cited 2021 Jul 28]; Available from: http://link.springer.com/10.1007/978-3-319-24277-4

8. Team R Development Core. A Language and Environment for Statistical Computing [Internet]. Vol. 2. R Foundation for Statistical Computing. Vienna, Austria; 2021. p. https://www.R-project.org. Available from: http://www.r-project.org

9. Fenniche S, Maalej S, Hassene H, Hantous S, Belhabib D, Bakkar S, et al. Presentation inhabituelle d’un thymolipome géant. Tunisie Med. 2003 Jun 1 [cited 2021 Jun 26]; 81(1): 59-62. Available from: https://europepmc.org/article/med/12708194

10. Rosado-de-Christenson ML, Pugatch RD, Moran CA, Galobardes J. Thymolipoma: Analysis of 27 cases. Radiology. 1994; 193(1): 121-126.

11. Moran CA, Rosado-De-Christenson M, Suster S. Thymolipoma: clinicopathologic review of 33 cases. Mod Pathol. 1995 Sep 1; 8(1): 741-744.

12. Rieker RJ, Schirmacher P, Schnabel PA, Moser K, Hoffmann H, Dienemann H, et al. Thymolipoma. A report of nine cases, with emphasis on its association with myasthenia gravis. Surg Today. 2000 Feb; 40(2): 132-136.

13. Huang CS, Li WY, Lee PC, Kao KP, Chou TY, Wu MH, et al. Analysis of outcomes following surgical treatment of thymolipomatous myasthenia gravis: Comparison with thymomatous and non-thymomatous myasthenia gravis. Interact Cardiovasc Thorac Surg. 2014; 18(4): 475-481.

14. Mourad OMA, de Andrade FM, Abrahão P, Monnerat A, Judice LF. Massa mediastinal gigante assimtomática: Um raro caso de timolipoma. J Bras Pneumol [Internet]. 2009 [cited 2021 Jun 26]; 35(10): 1049-1052. Available from: www.jornaldepneumologia.com.br

15. Obeso Carrillo GA, Garcia Fontán EM, Cañizares Carretero MA. Giant thymolipoma: case report of an unusual mediastinal tumor. Arch Bronconeumol [Internet]. 2014 Dec 1 [cited 2021 Jun 8]; 50(12): 557-559. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1579212914002380

16. Hull MT, Warfel KA, Kotylo P, Goheen MF, Brown JW. Proliferating thymolipoma: Ultrastructural, immunohistochemical, and flow cytometric study. Ultrastruct Pathol [Internet]. 1995 Jan 1 [cited 2021 Jun 26]; 19(1): 75-81. Available from: https://europepmc.org/article/med/7770964

17. Hudacko R, Aviv H, Langenfeld I, Fyle B. Thymolipoma: clues to pathogenesis revealed by cytogenetics. Ann Diagn Pathol [Internet]. 2009 Jun [cited 2021 Jun 8]; 13(3): 185-188. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0929940008000257

18. Shrivastava T, Ntiamoah P. Rare cause of large anterior mediastinal mass - Thymolipoma. Radiol Case Reports. 2020 Sep 5; 15(9): 1538-1540.

19. Goswami A, Baruah AR. Giant thymolipoma: A rare case presentation. Asian Cardiovasc Thorac Ann. 2017 Feb 1; 25(2): 143-145.

20. Yusuf Mohamad MF, Ahmed MA, Ali IH. Extensive mediastinal thymolipoma mimicking pulmonary edema. J Surg Case Reports. 2020 Apr 1; 2020(4).

21. Poursadeghfar M, Foroughi AA, Karamimaghm S. Thymolipoma-associated myasthenia gravis with high titer of Anti-MuSKAb: A case report. Int J Mol Med [Internet]. 2019 [cited 2021 Jun 25]; 8(1): 90-93. Available from: http://ijmcmd.org/article-1-1034-en.html

22. Takamori S, Hayashi A, Tayama K, Ohtsuka S, Hiraki H, Shimizu K. Thymolipoma associated with myasthenia gravis. Scand Cardiovasc J. 1997; 31(4): 241-242.

23. Santos E, Coutinho E, Martins da Silva A, Marinho O. Vasconcelos C, Taipa R, et al. Inflammatory myopathy associated with myasthenia gravis with and without thymic pathology: Report of four cases and literature review. Autoimmunity Reviews. Elsevier BV; 2017; 16: 644-649.

24. Gilhus NE, Verschuuren JI. Myasthenia gravis: Subgroup classification and therapeutic strategies. The Lancet Neurology. Lancet Publishing Group; 2015; 14: 1023-1036.

25. Diaz-Manera J, Rojas-García R, Gallardo E, Juárez C, Martínez-Domeño A, Martínez-Ramírez S, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan’s syndrome. Nat Clin Pract Neurol. 2007 Jul; 3(7): 405-410.

26. Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Seminars in Neurology. 2004; 24: 125-133.

27. Massuda T, Motomura M, Utsugisawa K, Nagane Y, Nakata R, Tokuda T, et al. Presentation inhabituelle d’un thymolipome géant. Tunisie Med. 2018 [cited 2021 Oct 15]: 1049-1052. Available from: www.journaldelpneumologia.com.br

28. Halon NJ, Jamieson B, Plunkett M, Kitchen CMR, Pham T, Krostad P. Thymic function and impaired maintenance of peripheral T cell populations in children with congenital heart disease and surgical thyromectomy. Pediatr Res. 2005 Jan; 57(1): 42-48.

29. Sauce D, Larsen M, Fastenackels S, Duperrier A, Keller M, Grubeck-Loebenstein B, et al. Evidence of premature immune aging in patients thymectomized during early childhood. J Clin Invest [Internet]. 2009 Oct 1 [cited 2021 Jun 25];19(10):3070–8. Available from: http://www.jci.org.